Physician profile
Andy A Aziz
NPI 1215021050
$1,312.19
in general payments reported to CMS, 2019-2025
17 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $53.21 · 2021: $360 · 2022: $262 · 2023: $219 · 2024: $97.47 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $298.72 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Kala Pharmaceuticals, INC. | $239.46 | 2019-2022 | |
| Harrow Eye, LLC | $172.56 | 2023-2024 | Iheezo, Vevye |
| Sun Pharmaceutical Industries INC. | $105.77 | 2019-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $95.70 | 2020-2021 | |
| Allergan, INC. | $93.83 | 2019-2022 | |
| Glaukos Corporation | $75.45 | 2025 | Idosetr |
| Abbvie INC. | $52.69 | 2022 | |
| Oyster Point Pharma, INC. | $27.09 | 2022 | |
| Bausch & Lomb Americas INC. | $22.61 | 2022 | |
| Ocular Therapeutix, INC. | $22.37 | 2023 | Dextenza |
| Dompe US, INC. | $21.06 | 2025 | Oxervate |
| Amgen INC. | $19.53 | 2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.22 | 2021 | |
| Biotissue Holdings INC. | $17.51 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $16.29 | 2019 | |
| Oasis Medical, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.